✦ LIBER ✦

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

✍ Scribed by Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller Jr; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman

Book ID: 117310424
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 258 KB
Volume: 380
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)60868-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dabrafenib in patients with Val600Glu or

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

✍ Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascie 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 259 KB

Subcuticular sutures versus staples for

Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, multicentre, open-label, randomised controlled trial

✍ Tsujinaka, Toshimasa; Yamamoto, Kazuyoshi; Fujita, Junya; Endo, Shunji; Kawada, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 262 KB

Homoharringtonine-based induction regime

Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial

✍ Jin, Jie; Wang, Jian-Xiang; Chen, Fei-Fei; Wu, De-Pei; Hu, Jiong; Zhou, Jian-Fen 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 395 KB

Adjuvant bevacizumab in patients with me

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

✍ Corrie, Pippa G; Marshall, Andrea; Dunn, Janet A; Middleton, Mark R; Nathan, Pau 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 361 KB

Vemurafenlb Improves Overall Survival Co

Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial

✍ G. McArthur; A. Hauschild; C. Robert; J.B. Haanen; P. Ascierto; R.J. Lee; K. Nol 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Axitinib versus sorafenib as first-line

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB